Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley Stage 1 Hidradenitis Suppurativa: prospective short-term trial and one-year follow-up in 28 consecutive patients

Maïa Delage (1, 2) , J.-P. Jais (3, 4) , T. Lam (1, 2) , H. Guet-Revillet (5) , Marie-Noëlle Ungeheuer (6) , Paul-Henri Consigny (1, 2) , Aude Nassif (1, 2) , O. Join-Lambert (7)

1 CMIP - Centre Médical de l'Institut Pasteur
2 Centre d'infectiologie Necker-Pasteur [CHU Necker]
3 Service d'informatique médicale et biostatistiques [CHU Necker]
4 Imagine - U1163 - Imagine - Institut des maladies génétiques (IHU)
5 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
6 ICAReB - Investigation Clinique et d’Accès aux Ressources Biologiques (Plate-forme) - Clinical Investigation and Access to BioResources
7 GRAM 2.0 - Groupe de Recherche sur l'Adaptation Microbienne

Domaines: Sciences du Vivant [q-bio]; Médecine humaine et pathologie; Dermatologie

Maïa Delage, J.-P. Jais, T. Lam, H. Guet-Revillet, Marie-Noëlle Ungeheuer, et al.. Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley Stage 1 Hidradenitis Suppurativa: prospective short-term trial and one-year follow-up in 28 consecutive patients. Journal of The American Academy of Dermatology, 2020, ⟨10.1016/j.jaad.2020.01.007⟩. ⟨pasteur-02547275⟩